Adalvo is delighted to announce the successful DCP submission for Nintedanib 100mg & 150mg soft gel capsules. Our product is being developed in collaboration with our sister Company, which forms part of the Aztiq group.
Our product has been developed based on two reference brands: Ofev 100mg & 150mg soft gel capsules which is indicated for the treatment of Idiopathic Pulmonary Fibrosis and Vargatef 100mg & 150mg soft gel capsules which is indicated in the treatment of Non-Small Cell Lung Cancer.
Both brands sell at around $3.1bn annually in 2021, at a global level, combined. (according to IQVIA)
Based on our positive results, we expect to be amongst the first Companies to market this product in all our major markets, with both indications.